☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Chronic Graft-Versus-Host Disease
Incyte Enters into an Exclusive WW License Agreement with Syndax to Develop and Commercialize Axatilimab for cGVHD and Other Fibro...
September 27, 2021
Incyte's Jakafi (ruxolitinib) Receives the US FDA's Approval for the Treatment of Chronic Graft-Versus-Host Disease
September 23, 2021
Incyte and Novartis Publish Results of Jakafi (ruxolitinib) in P-III REACH3 Study to Treat Chronic Graft-Versus-Host Disease in NE...
July 15, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.